Dharti Proteins 1:1 bonus issue: EGM set for Nov 6

What the company has announced

Dharti Proteins has scheduled an Extraordinary General Meeting (EGM) on Nov 6 to seek approval for a 1:1 bonus issue. The update sits alongside a series of corporate disclosures filed in early October, including board meeting intimations and amendments to the company’s constitutional documents.

The bonus proposal follows a board meeting agenda that included the company’s quarterly numbers and a bonus consideration item. On 13 Oct 2026, Dharti Proteins indicated a board meeting for Quarterly Results & Bonus issue, aligning the earnings event with the bonus proposal process.

For investors, the immediate takeaway is that the bonus is still within the shareholder approval cycle and is being supported by formal disclosures under the listing framework.

Stock snapshot and immediate context

On 13 Oct 2026, Dharti Proteins’ reported LTP was 66.92, up 4.99%. The move coincided with the company’s calendar marking Q2 FY2027 board meeting related updates.

While the disclosures do not detail record dates, ex-bonus timelines, or the quantum of reserves, the presence of an EGM date indicates the proposal is being taken through required shareholder approvals.

Board meeting on Oct 13: results and bonus consideration

A board meeting was intimated for Tuesday, 13 Oct 2026. The disclosure explicitly linked the meeting to two items: approval of Q2/H1 FY27 results and consideration of bonus shares.

This sequencing is typical in corporate actions where a board first considers and recommends an action, after which shareholder approval is sought via an EGM or AGM, depending on the agenda and timing.

Dharti Proteins’ own calendar also shows Q2 2027 Earnings Release dated 10/13/2026, reinforcing that the same date carried earnings-related significance.

EGM on Nov 6: what “1:1 bonus” implies

The company has set an EGM for Nov 6 to approve a 1:1 bonus issue. A 1:1 bonus issue generally means one additional equity share is proposed for every one existing equity share held, subject to the terms approved by shareholders.

The disclosure available here does not specify the record date, eligibility criteria cut-off, or any expected timetable beyond the EGM date. Investors typically watch for follow-up filings that contain operational details once approvals are in place.

Regulatory disclosures filed in early October

Dharti Proteins made multiple filings in the week leading up to the Oct 13 board meeting. These disclosures included board meeting intimation and changes relating to its Memorandum and Articles of Association.

On 8 Oct, the company filed an announcement under Regulation 30 (LODR) regarding amendments to the Memorandum & Articles of Association. The filing stated that the ROC approved the company’s object clause alteration on 6 Oct 2026, following a special resolution passed at the 28 Sep 2026 AGM.

Separately, the company’s disclosures also referenced adoption of a new set of MOA & AOA under Regulation 30 dated 30 Sep 2026.

BSE trading approval for additional shares

On 7 Oct 2026, Dharti Proteins disclosed that BSE Limited approved trading in 5,00,000 equity shares of Rs 10 each. The approval was stated to be effective from Oct 8, 2026.

The disclosure described this approval in the context of resolution plan restructuring. Beyond this, no further operational detail is provided in the given text, but the approval indicates that the exchange granted permission for the specified shares to be admitted for trading.

Key facts at a glance

Why the cluster of filings matters

The disclosures show the company moving through multiple compliance and corporate housekeeping items close together: board meeting intimation, governance document updates, and exchange approvals for share trading.

For market participants, such a sequence typically signals that the company is aligning corporate actions with regulatory requirements under the LODR framework and exchange processes. The explicit reference to ROC approval and AGM special resolution adds formal context to the MOA/AOA changes, which are often prerequisites when a company updates its objects, business scope, or governance clauses.

Market impact: what investors can track from here

From the information available, the market-relevant milestones are clear: the Oct 13 board meeting that included results and bonus consideration, and the Nov 6 EGM set to approve the 1:1 bonus issue.

In addition, the BSE approval for trading in 5,00,000 equity shares from Oct 8 provides another data point for investors watching changes in listed share capital admitted for trading. However, the disclosure does not link this directly to the proposed bonus issue.

Investors tracking Dharti Proteins may now focus on subsequent exchange filings that typically follow shareholder meetings, particularly those confirming outcomes of the EGM and any detailed corporate action timetable if announced.

Conclusion

Dharti Proteins has placed a 1:1 bonus issue before shareholders with an EGM scheduled for Nov 6, after indicating that the matter would be considered alongside Q2/H1 FY27 results at the 13 Oct 2026 board meeting. The company’s October disclosures also covered ROC-approved amendments to MOA/AOA and BSE trading approval for 5,00,000 equity shares effective Oct 8.

The next confirmed step on the calendar is the EGM, where shareholders are set to vote on the bonus proposal.